Gilead   4Q Revenues: $8.5 billion (+16%)   4Q Earnings: $4.7 billion (+34%)   FY Revenues: $32.6 billion (+31%)   FY Earnings: $18.1 billion (+50%)   Comments: Growth in the quarter was driven by Harvoni with sales of $3.3 billion, up 59%, and partially offset by Sovaldi sales ($1.5 billion, down 11%). Antiviral product sales, which include products for HIV and liver diseases, were $7.9 billion in the quarter, up 18%, primarily as a result of the launch of HCV products in Japan and co...